[{"id":"38ae3e19-8dad-4b01-a570-b25b5bcb525a","acronym":"","url":"https://clinicaltrials.gov/study/NCT06919666","created_at":"2025-06-21T13:16:45.845Z","updated_at":"2025-06-21T13:16:45.845Z","phase":"Phase 1/2","brief_title":"NT219 Combined With Standard of Care Biologic Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma","source_id_and_acronym":"NCT06919666","lead_sponsor":"University of Colorado, Denver","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Erbitux (cetuximab) • NT219"],"overall_status":"Recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 06/01/2025","start_date":" 06/01/2025","primary_txt":" Primary completion: 02/01/2030","primary_completion_date":" 02/01/2030","study_txt":" Completion: 02/01/2031","study_completion_date":" 02/01/2031","last_update_posted":"2025-06-18"},{"id":"626de316-d799-4804-9309-0166aa718911","acronym":"NCI-2018-01296","url":"https://clinicaltrials.gov/study/NCT02983578","created_at":"2021-01-18T14:40:40.387Z","updated_at":"2025-02-25T15:07:25.564Z","phase":"Phase 2","brief_title":"Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer","source_id_and_acronym":"NCT02983578 - NCI-2018-01296","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CD8 • STAT3","pipe":" | ","alterations":" PD-L1 expression • STAT3 expression","tags":["CD8 • STAT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • STAT3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • danvatirsen (AZD9150)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 39","initiation":"Initiation: 03/02/2017","start_date":" 03/02/2017","primary_txt":" Primary completion: 04/30/2025","primary_completion_date":" 04/30/2025","study_txt":" Completion: 04/30/2025","study_completion_date":" 04/30/2025","last_update_posted":"2024-08-27"},{"id":"ffb136f1-6291-45e5-a40d-c7db3edb36d9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05986240","created_at":"2023-08-14T15:09:52.950Z","updated_at":"2024-07-02T16:34:27.038Z","phase":"Phase 1","brief_title":"Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS \u0026 AML","source_id_and_acronym":"NCT05986240","lead_sponsor":"Montefiore Medical Center","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • danvatirsen (AZD9150)"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 05/08/2024","start_date":" 05/08/2024","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2024-06-12"},{"id":"3c4b70e5-0095-4941-b867-c448ada0131d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05879250","created_at":"2023-05-30T14:05:05.692Z","updated_at":"2024-07-02T16:34:59.705Z","phase":"Phase 2","brief_title":"WP1066 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma","source_id_and_acronym":"NCT05879250","lead_sponsor":"Northwestern University","biomarkers":" IDH1 • MGMT","pipe":" | ","alterations":" RAS wild-type • IDH wild-type","tags":["IDH1 • MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RAS wild-type • IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e WP1066"],"overall_status":"Recruiting","enrollment":" Enrollment 39","initiation":"Initiation: 05/22/2024","start_date":" 05/22/2024","primary_txt":" Primary completion: 12/27/2027","primary_completion_date":" 12/27/2027","study_txt":" Completion: 12/27/2028","study_completion_date":" 12/27/2028","last_update_posted":"2024-05-31"},{"id":"e065d086-8c9a-4bc6-895e-ec02b787c8d1","acronym":"PEMDA-HN","url":"https://clinicaltrials.gov/study/NCT05814666","created_at":"2023-04-18T15:04:16.845Z","updated_at":"2024-07-02T16:34:59.660Z","phase":"Phase 2","brief_title":"Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC","source_id_and_acronym":"NCT05814666 - PEMDA-HN","lead_sponsor":"Flamingo Therapeutics NV","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • danvatirsen (AZD9150)"],"overall_status":"Recruiting","enrollment":" Enrollment 81","initiation":"Initiation: 05/30/2023","start_date":" 05/30/2023","primary_txt":" Primary completion: 05/30/2025","primary_completion_date":" 05/30/2025","study_txt":" Completion: 05/30/2026","study_completion_date":" 05/30/2026","last_update_posted":"2024-05-31"},{"id":"06c95d25-232d-4edf-bad2-62ebafe8d024","acronym":"","url":"https://clinicaltrials.gov/study/NCT04474470","created_at":"2021-01-18T21:29:42.332Z","updated_at":"2024-07-02T16:35:04.621Z","phase":"Phase 1/2","brief_title":"A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer","source_id_and_acronym":"NCT04474470","lead_sponsor":"TyrNovo Ltd.","biomarkers":" KRAS • BRAF","pipe":" | ","alterations":" KRAS wild-type • RAS wild-type • RAS wild-type + BRAF wild-type","tags":["KRAS • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type • RAS wild-type • RAS wild-type + BRAF wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • NT219"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 110","initiation":"Initiation: 09/03/2020","start_date":" 09/03/2020","primary_txt":" Primary completion: 05/08/2024","primary_completion_date":" 05/08/2024","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2024-05-09"},{"id":"cb6b89eb-4f9f-4788-a9df-5a300e0272bd","acronym":"","url":"https://clinicaltrials.gov/study/NCT04049825","created_at":"2021-01-18T19:51:38.271Z","updated_at":"2024-07-02T16:35:06.344Z","phase":"Phase 1","brief_title":"A Phase 1 Trial of OPB-111077 in Combination With Bendamustine and Rituximab in Patients With r/r DLBCL","source_id_and_acronym":"NCT04049825","lead_sponsor":"Otsuka Pharmaceutical Co., Ltd.","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • bendamustine • OPB-111077"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 11/22/2019","start_date":" 11/22/2019","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2024-05-02"},{"id":"942a4b1b-75eb-4eb8-9957-11d7427ae86e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03195699","created_at":"2021-01-18T15:45:29.539Z","updated_at":"2024-07-02T16:35:10.349Z","phase":"Phase 1","brief_title":"Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers","source_id_and_acronym":"NCT03195699","lead_sponsor":"Tvardi Therapeutics, Incorporated","biomarkers":" PD-1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TTI-101 oral"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 11/15/2017","start_date":" 11/15/2017","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-04-10"},{"id":"46872237-6ce2-4f9c-9626-78292d387d52","acronym":"CanStem111P trial","url":"https://clinicaltrials.gov/study/NCT02993731","created_at":"2023-11-15T19:14:20.299Z","updated_at":"2024-07-02T16:35:29.170Z","phase":"Phase 3","brief_title":"A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma","source_id_and_acronym":"NCT02993731 - CanStem111P trial","lead_sponsor":"Sumitomo Pharma America, Inc.","biomarkers":" STAT3","pipe":"","alterations":" ","tags":["STAT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • albumin-bound paclitaxel • napabucasin (BBI608)"],"overall_status":"Completed","enrollment":" Enrollment 1134","initiation":"Initiation: 12/01/2016","start_date":" 12/01/2016","primary_txt":" Primary completion: 03/01/2020","primary_completion_date":" 03/01/2020","study_txt":" Completion: 03/01/2020","study_completion_date":" 03/01/2020","last_update_posted":"2023-11-15"},{"id":"657a150b-5f41-44b4-ab84-352d511b0114","acronym":"","url":"https://clinicaltrials.gov/study/NCT01325441","created_at":"2021-01-18T05:23:55.341Z","updated_at":"2024-07-02T16:35:29.056Z","phase":"Phase 1/2","brief_title":"A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies","source_id_and_acronym":"NCT01325441","lead_sponsor":"Sumitomo Pharma America, Inc.","biomarkers":" BRAF • ER • ALK • PGR","pipe":" | ","alterations":" HER-2 positive • BRAF V600E • HER-2 negative • BRAF V600 • ALK positive • BRAF V600K • BRAF wild-type • ER negative • EGFR positive • PGR negative","tags":["BRAF • ER • ALK • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • BRAF V600E • HER-2 negative • BRAF V600 • ALK positive • BRAF V600K • BRAF wild-type • ER negative • EGFR positive • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • albumin-bound paclitaxel • napabucasin (BBI608)"],"overall_status":"Completed","enrollment":" Enrollment 565","initiation":"Initiation: 04/01/2011","start_date":" 04/01/2011","primary_txt":" Primary completion: 06/01/2021","primary_completion_date":" 06/01/2021","study_txt":" Completion: 06/01/2021","study_completion_date":" 06/01/2021","last_update_posted":"2023-11-15"},{"id":"8a45fead-cf37-4fe6-b1b4-3275fc24166b","acronym":"","url":"https://clinicaltrials.gov/study/NCT01776307","created_at":"2021-01-18T07:50:01.225Z","updated_at":"2024-07-02T16:35:29.131Z","phase":"Phase 2","brief_title":"A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer","source_id_and_acronym":"NCT01776307","lead_sponsor":"Sumitomo Pharma America, Inc.","biomarkers":" KRAS • RAS","pipe":" | ","alterations":" RAS wild-type","tags":["KRAS • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Vectibix (panitumumab) • capecitabine • napabucasin (BBI608)"],"overall_status":"Completed","enrollment":" Enrollment 200","initiation":"Initiation: 03/01/2012","start_date":" 03/01/2012","primary_txt":" Primary completion: 06/01/2018","primary_completion_date":" 06/01/2018","study_txt":" Completion: 04/01/2020","study_completion_date":" 04/01/2020","last_update_posted":"2023-11-15"},{"id":"b12985dc-ad65-43ed-8d9c-667f21a6d1b1","acronym":"","url":"https://clinicaltrials.gov/study/NCT02024607","created_at":"2021-01-18T09:15:39.668Z","updated_at":"2024-07-02T16:35:29.143Z","phase":"Phase 1/2","brief_title":"A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer","source_id_and_acronym":"NCT02024607","lead_sponsor":"Sumitomo Pharma America, Inc.","biomarkers":" KRAS","pipe":" | ","alterations":" RAS wild-type","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • 5-fluorouracil • capecitabine • Stivarga (regorafenib) • oxaliplatin • irinotecan • leucovorin calcium • napabucasin (BBI608) • fluorouracil topical"],"overall_status":"Completed","enrollment":" Enrollment 495","initiation":"Initiation: 01/01/2014","start_date":" 01/01/2014","primary_txt":" Primary completion: 03/01/2019","primary_completion_date":" 03/01/2019","study_txt":" Completion: 11/01/2019","study_completion_date":" 11/01/2019","last_update_posted":"2023-11-15"},{"id":"d2aeb8e6-4453-4c46-8189-8e256a9cca01","acronym":"CO23","url":"https://clinicaltrials.gov/study/NCT01830621","created_at":"2021-01-18T08:08:24.045Z","updated_at":"2024-07-02T16:35:38.911Z","phase":"Phase 3","brief_title":"BBI608 and Best Supportive Care vs Placebo and Best Supportive Care in Pretreated Advanced Colorectal Carcinoma","source_id_and_acronym":"NCT01830621 - CO23","lead_sponsor":"NCIC Clinical Trials Group","biomarkers":" KRAS","pipe":" | ","alterations":" RAS wild-type","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e napabucasin (BBI608)"],"overall_status":"Completed","enrollment":" Enrollment 282","initiation":"Initiation: 05/10/2013","start_date":" 05/10/2013","primary_txt":" Primary completion: 05/07/2016","primary_completion_date":" 05/07/2016","study_txt":" Completion: 05/16/2016","study_completion_date":" 05/16/2016","last_update_posted":"2023-08-28"},{"id":"bc7aacf6-15f4-4469-9347-6ccef9c490f0","acronym":"","url":"https://clinicaltrials.gov/study/NCT01066663","created_at":"2021-01-18T04:12:15.086Z","updated_at":"2024-07-02T16:35:54.983Z","phase":"Phase 1/2","brief_title":"Pyrimethamine for the Treatment of Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","source_id_and_acronym":"NCT01066663","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" CCND1 • CD5 • FCER2","pipe":" | ","alterations":" Chr t(11;14)","tags":["CCND1 • CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14)"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 03/01/2010","start_date":" 03/01/2010","primary_txt":" Primary completion: 02/01/2022","primary_completion_date":" 02/01/2022","study_txt":" Completion: 01/01/2023","study_completion_date":" 01/01/2023","last_update_posted":"2023-02-22"},{"id":"4992c086-2aab-4254-878a-7ce1b1e555fb","acronym":"","url":"https://clinicaltrials.gov/study/NCT04334863","created_at":"2021-01-18T20:59:17.912Z","updated_at":"2024-07-02T16:35:55.122Z","phase":"Phase 1","brief_title":"WP1066 in Children With Refractory and Progressive or Recurrent Malignant Brain Tumors","source_id_and_acronym":"NCT04334863","lead_sponsor":"Emory University","biomarkers":" STAT3","pipe":"","alterations":" ","tags":["STAT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e WP1066"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 05/04/2020","start_date":" 05/04/2020","primary_txt":" Primary completion: 02/03/2023","primary_completion_date":" 02/03/2023","study_txt":" Completion: 02/03/2023","study_completion_date":" 02/03/2023","last_update_posted":"2023-02-21"},{"id":"54accd08-1a26-4357-b09a-9c2d8e7f781a","acronym":"","url":"https://clinicaltrials.gov/study/NCT01904123","created_at":"2021-01-18T08:34:31.425Z","updated_at":"2024-07-02T16:36:14.851Z","phase":"Phase 1","brief_title":"STAT3 Inhibitor WP1066 in Treating Patients With Recurrent Malignant Glioma or Progressive Metastatic Melanoma in the Brain","source_id_and_acronym":"NCT01904123","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF positive","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e WP1066"],"overall_status":"Completed","enrollment":" Enrollment 8","initiation":"Initiation: 07/13/2018","start_date":" 07/13/2018","primary_txt":" Primary completion: 03/16/2022","primary_completion_date":" 03/16/2022","study_txt":" Completion: 03/16/2022","study_completion_date":" 03/16/2022","last_update_posted":"2022-03-23"},{"id":"044ad04e-9242-4d5c-b71d-62ab6ac33aad","acronym":"STEM","url":"https://clinicaltrials.gov/study/NCT02970682","created_at":"2021-01-18T14:36:07.066Z","updated_at":"2024-07-02T16:36:58.181Z","phase":"Phase 2","brief_title":"SFX-01 in the Treatment and Evaluation of Metastatic Breast Cancer","source_id_and_acronym":"NCT02970682 - STEM","lead_sponsor":"Evgen Pharma","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tamoxifen • fulvestrant • Sulforadex (sulforafan alfadex)"],"overall_status":"Completed","enrollment":" Enrollment 60","initiation":"Initiation: 10/01/2016","start_date":" 10/01/2016","primary_txt":" Primary completion: 01/01/2019","primary_completion_date":" 01/01/2019","study_txt":" Completion: 03/01/2019","study_completion_date":" 03/01/2019","last_update_posted":"2019-07-12"},{"id":"0aa17be4-1019-48c2-aae6-8e7c68526412","acronym":"","url":"https://clinicaltrials.gov/study/NCT03522649","created_at":"2022-06-12T05:56:57.860Z","updated_at":"2024-07-02T16:36:58.810Z","phase":"Phase 3","brief_title":"A Phase III Clinical Study of Napabucasin (GB201) Plus FOLFIRI in Adult Patients With Metastatic Colorectal Cancer","source_id_and_acronym":"NCT03522649","lead_sponsor":"1Globe Health Institute LLC","biomarkers":" CTNNB1 • STAT3","pipe":"","alterations":" ","tags":["CTNNB1 • STAT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • irinotecan • leucovorin calcium • napabucasin (BBI608)"],"overall_status":"Unknown status","enrollment":" Enrollment 668","initiation":"Initiation: 04/12/2018","start_date":" 04/12/2018","primary_txt":" Primary completion: 11/01/2021","primary_completion_date":" 11/01/2021","study_txt":" Completion: 11/01/2021","study_completion_date":" 11/01/2021","last_update_posted":"2019-06-18"},{"id":"34daa706-9096-4fce-9a76-dd0af1cf295c","acronym":"","url":"https://clinicaltrials.gov/study/NCT01563302","created_at":"2021-01-18T06:37:34.260Z","updated_at":"2025-02-25T15:05:13.817Z","phase":"Phase 1/2","brief_title":"Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to Patients With Advanced Cancers","source_id_and_acronym":"NCT01563302","lead_sponsor":"Ionis Pharmaceuticals, Inc.","biomarkers":" STAT3","pipe":"","alterations":" ","tags":["STAT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e danvatirsen (AZD9150)"],"overall_status":"Completed","enrollment":" Enrollment 64","initiation":"Initiation: 02/27/2012","start_date":" 02/27/2012","primary_txt":" Primary completion: 03/23/2016","primary_completion_date":" 03/23/2016","study_txt":" Completion: 03/23/2016","study_completion_date":" 03/23/2016","last_update_posted":"2018-06-25"},{"id":"11a75896-ed72-4de4-bf64-92a7e752fb1f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03158324","created_at":"2021-01-18T15:34:16.926Z","updated_at":"2024-07-02T16:37:21.037Z","phase":"Phase 2a","brief_title":"Phase IIa Dose-Expansion and Biomarker Study of OPB-111077","source_id_and_acronym":"NCT03158324","lead_sponsor":"National University Hospital, Singapore","biomarkers":" EGFR • BRAF • ALK • EML4 • SIRT1","pipe":" | ","alterations":" EGFR mutation • BRAF mutation • ALK positive • EML4-ALK fusion • ALK fusion • ALK mutation • RET mutation","tags":["EGFR • BRAF • ALK • EML4 • SIRT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • BRAF mutation • ALK positive • EML4-ALK fusion • ALK fusion • ALK mutation • RET mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e OPB-111077"],"overall_status":"Unknown status","enrollment":" Enrollment 52","initiation":"Initiation: 05/22/2017","start_date":" 05/22/2017","primary_txt":" Primary completion: 05/22/2020","primary_completion_date":" 05/22/2020","study_txt":" Completion: 11/30/2020","study_completion_date":" 11/30/2020","last_update_posted":"2017-06-15"}]